Publications by authors named "M E Evers"

We developed a novel adeno-associated virus 5 gene therapy (AAV5-GLA) expressing human alpha-galactosidase A (GLA) under the control of a novel, small and strong, liver-restricted promoter. We assessed the preclinical potential of AAV5-GLA for treating Fabry disease, an X-linked hereditary metabolic disorder resulting from mutations in the gene encoding GLA that lead to accumulation of the substrates globotriaosylceramide and globotriaosylsphingosine, causing heart, kidney, and central nervous system dysfunction. Effects of intravenously administered AAV5-GLA were evaluated in (1) GLA-knockout mice aged 7-8 weeks (early in disease) and 20 weeks (nociception phenotype manifestation) and (2) cynomolgus macaques during an 8-week period.

View Article and Find Full Text PDF

The lung is one of the most frequently metastasized organs from various cancer entities, especially colorectal cancer (CRC). The occurrence of lung metastasis correlates with worse prognosis in CRC patients. Here, we aimed to investigate the role of IL-10 in lung metastasis development and identify the cellular source and target cells of IL-10 during lung metastatic establishment.

View Article and Find Full Text PDF

Currently, central nervous system tumors are diagnosed with an integrated diagnostic approach that combines histopathological examination with molecular genetic profiling, which requires days to weeks to achieve a precise and informative classification of CNS tumors. This study demonstrates the feasibility of rapid multiplex amplicon nanopore sequencing for identifying critical mutations relevant to molecular stratification of brain tumors within the timeframe of standard resection surgery. Utilizing live analysis of nanopore sequencing data, we evaluated the brain tumor-associated molecular markers IDH1 R132, IDH2 R172, C228 and C250, H3F3A K27 and G34, Hist1H3B K27, and BRAF V600.

View Article and Find Full Text PDF
Article Synopsis
  • - Recombinant adeno-associated virus (rAAV) gene therapies have great potential for treating various genetic disorders, requiring ongoing innovation in their development.
  • - The novel miQURE technology utilizes microRNAs to target and silence toxic genes, and has evolved into the linQURE platform, which allows for simultaneous control of multiple gene expressions.
  • - By demonstrating the capability to express two synthetic miRNAs together, linQURE enhances the effectiveness of gene therapy for complex diseases with multiple genetic contributors, ultimately broadening treatment options.
View Article and Find Full Text PDF